# Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

> **NCT02363283** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 37 (actual)

## Conditions studied

- Recurrent Uveal Melanoma
- Stage IV Uveal Melanoma AJCC v7

## Interventions

- **DRUG:** Glembatumumab Vedotin
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02363283
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-16
- **Primary completion:** 2018-07-02
- **Final completion:** 2018-07-02
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2020-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02363283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02363283, "Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02363283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*